StocksMedium•4 November 2026•
1 min read
ADC Therapeutics Shares Gain on Strong ZYNLONTA Clinical Data
Key Facts
1ADC Therapeutics announced LOTIS-7 trial data showing an 88.7% overall response rate for ZYNLONTA plus glofitamab.
2Data will be featured in 5 oral presentations at the 68th ASH Annual Meeting in December.
ADC Therapeutics announced LOTIS-7 trial data showing an 88.7% overall response rate for ZYNLONTA plus glofitamab. According to a company statement via PR Newswire, the data will be featured in 5 oral presentations at the 68th ASH Annual Meeting.
ADCT closed at $1.55 on November 3, 2026, after reaching a day high of $1.66 and a low of $1.53. The strong clinical efficacy for the ZYNLONTA program highlights the company's antibody-drug conjugate pipeline ahead of the ASH Annual Meeting scheduled for December.